tiprankstipranks
Trending News
More News >
Apellis Pharmaceuticals (APLS)
NASDAQ:APLS
US Market

Apellis Pharmaceuticals (APLS) Income Statement

Compare
983 Followers

Apellis Pharmaceuticals Income Statement

Last quarter (Q3 2025), Apellis Pharmaceuticals's total revenue was $458.58M, an increase of 132.98% from the same quarter last year. In Q3, Apellis Pharmaceuticals's net income was $215.72M. See Apellis Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 781.37M$ 396.59M$ 75.42M$ 66.56M$ 250.65M
Gross Profit
$ 663.64M$ 338.08M$ 69.79M$ 61.36M$ 225.60M
Operating Expenses
$ 828.62M$ 855.20M$ 664.40M$ 597.64M$ 439.32M
Depreciation and Amortization
$ 1.80M$ 1.70M$ 1.49M$ 1.49M$ 859.00K
EBITDA
$ -154.53M$ -495.21M$ -617.39M$ -731.27M$ -312.23M
Operating Income
$ -164.98M$ -517.12M$ -594.61M$ -536.28M$ -213.73M
Other Income/Expenses
$ -31.74M$ -9.38M$ -56.89M$ -209.72M$ -129.30M
Pretax Income
$ -196.72M$ -526.50M$ -651.50M$ -746.00M$ -343.03M
Net Income
$ -197.88M$ -528.63M$ -652.17M$ -746.35M$ -344.87M
Per Share Metrics
Basic EPS
$ -1.60$ -4.45$ -6.15$ -8.84$ -4.59
Diluted EPS
$ -1.60$ -4.45$ -6.15$ -8.84$ -4.59
Weighted Average Shares Outstanding
123.91M 118.68M 106.11M 84.42M 75.16M
Weighted Average Shares Outstanding (Diluted)
123.91M 118.68M 106.11M 84.42M 75.16M
Currency in USD

Apellis Pharmaceuticals Earnings and Revenue History